• DJIA41,317.43+564.47(1.39%)
  • NASDAQ17,977.73+266.99(1.51%)
  • S&P 5005,686.67+82.53(1.47%)
*Delayed 10 minutes
  • US 10 Year*111.23-0.62(-0.56%)
  • Crude Oil*58.38-0.86(-1.45%)
  • Gold3,247.40+25.20(0.78%)
*Delayed 10 minutes
  • DJIA Futures*41,436.00+581.00(1.42%)
  • NASDAQ Futures*20,204.50+333.75(1.68%)
  • S&P 500 Futures*5,710.50+87.25(1.55%)
*Delayed 10 minutes
Research & Quotes
Search a symbol
Viatris
$8.65
XNMS
+0.18(+2.13%)
As of May-02-20254:00:00 PM ET
Bid x size (XNMS)
$8.52 x 1
Volume
11,937,132
Ask x size (ARCX)
$8.68 x 6
10/90-day avg. volume
12M / 13M
Day range
current range, $72.73%
low
$8.52
high
$8.74
52-week range
current range, $27.31%
$6.85
$13.55

Detailed quote

Open
$8.66
Previous close As of May-01-2025
$8.47
Equity Summary Score
P/E ratio
0.00
Current dividend/ex-date
$0.12 / Mar-10-2025
Estimated dividend rate/yield
$0.48 / 5.6671%
Market cap.
Medium Cap ($10.04B)
Shares outstanding
1.2B
Index
SP500
Primary exchange
NASDAQ-NMS
Instrument type
Common Stock
CUSIP

Your positions with VTRS

Chart

Please Wait
Select Technical Analysis Term
| 30M 1D 1W
Show Indicators Data provided by Trading Central |
Our Preference Alternative Comments
to
6M
Timeframe
  • 1D
  • 1M
  • 6M
  • 1Y
  • 5Y
  • 10Y
  • MAX
Frequency (Daily)
Frequency
  • Daily
  • Weekly
  • 5 Minutes
  • 10 Minutes
  • 15 Minutes
  • 30 Minutes
  • 1 Hour
  • 4 Hours
  • Monthly
  • Quarterly
  • Yearly
(right-click to deleteright-click to manage)(long-press to drag)(drag to change anchor time)
  • N/A
  • O: N/A
  • H: N/A
  • L: N/A
  • C: N/A
  • V: N/A
Detach Attach
Select Tool
None
1
2
3
Axis Label:
Span Panels:
Show Callout:
I B 12px 8 10 12 13 14 16 20 28 36 48 64 Helvetica, sans-serif Default Helvetica Courier Garamond Palatino Times New Roman Settings Settings Settings
Done Editing

WAVE TEMPLATE
WAVE TEMPLATE Grand Supercycle Supercycle Cycle Primary Intermediate Minor Minute Minuette Sub-Minuette Custom
IMPULSE
IMPULSE - - - I II III IV V i ii iii iv v 1 2 3 4 5 A B C D E a b c d e W X Y X Z w x y x z
CORRECTIVE
CORRECTIVE - - - A B C a b c W X Y w x y
None Parentheses Enclosed
Show Lines:
Save Config
Restore Config
to
6M
Timeframe
  • 1D
  • 1M
  • 6M
  • 1Y
  • 5Y
  • 10Y
  • MAX
Frequency (Daily)
Frequency
  • Daily
  • Weekly
  • 5 Minutes
  • 10 Minutes
  • 15 Minutes
  • 30 Minutes
  • 1 Hour
  • 4 Hours
  • Monthly
  • Quarterly
  • Yearly

Price performance

5-day
6.40%
10-day
14.42%
1-month
0.58%
3-month
-23.32%
6-month
-25.56%
YTD
-30.52%
1-year
-25.62%
2-year
-7.59%
5-year
--
10-year
--

Company profile

Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers prescription brand drugs, generic drugs, complex generic drugs, and biosimilars. It also provides drugs in various therapeutic areas covering various noncommunicable and infectious diseases, including cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, eye care, gastroenterology, immunology, oncology, and respiratory and allergy, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. In addition, the company offers medicines in the form of oral solid doses, injectables, and complex dosage forms to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. It distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. The company sells its products under the Lyrica, Lipitor, Celebrex, Viagra, Creon, Influvac, Wixela Inhub, EpiPen Auto-Injector, Fraxiparine, Yupelri, Norvasc, Amitiza, Effexor, Lipacreon, Zoloft, Xalabrands, Dymista, Xanax, and Breyna brands. It has collaboration agreements with Mapi Pharma Ltd. to develop and commercialize long-acting glatiramer acetate depot products and additional products; Revance Therapeutics, Inc. to develop, manufacture, and commercialize a biosimilar to the branded biologic product, BOTOX; and Theravance Biopharma, Inc. to develop and commercialize revefenacin. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.

Events

Loading

Short interest

Stock markets are volatile and can fluctuate significantly in response to company, industry, political, regulatory, market, or economic developments. Investing in stock involves risks, including the loss of principal.

The Equity Summary Score provided by LSEG StarMine is current as of the date specified. There may be differences between the Equity Summary Score analyst count and the number of underlying analysts listed. Due to the timing in receiving ratings changes into the Equity Summary Score model, the Equity Summary Score analyst count may lag the ratings count displayed by one or more days. There may also be analyst count variations for symbols with multiple share classes and ADRs. More details on Equity Summary Score calculation are included in the Understanding and Using the Equity Summary Score Methodology (PDF).

The Equity Summary Score is provided for informational purposes only, does not constitute advice or guidance, and is not an endorsement or recommendation for any particular security or trading strategy. The Equity Summary Score is provided by LSEG StarMine, an independent company not affiliated with Fidelity Investments. For more information and details, go to Fidelity.com.

As with all your investments through Fidelity, you must make your own determination whether an investment in any particular security or securities is consistent with your investment objectives, risk tolerance, financial situation, and evaluation of the security. Fidelity is not recommending or endorsing this investment by making it available to its customers.

Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News and headlines are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that the information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

Fidelity Brokerage Services LLC, Member NYSE, SIPC, 900 Salem Street, Smithfield, RI 02917

1144475.2.1